PCV51 A COST-EFFECTIVENESS ASSESSMENT OF DALTEPARIN AS A PROPHYLACTIC AND THERAPEUTIC AGENT FOR THE MANAGEMENT OF THROMBOEMBOLIC VENOUS DISEASE (VTE) IN MEXICAN ADULT PATIENTS AFTER TOTAL HIP REPLACEMENT
Abstract
Authors
H Arreola-Ornelas AA Rosado-Buzzo MDL Garca-Mollinedo J Dorantes-Aguilar J Mould-Quevedo G Davila-Loaiza